Analyst consensus points to Q2 2026 revenue of $80.0 million and an EPS of -$0.01, while the current stock price of $20.51 trades significantly below the average analyst target of $27.00.
Investors are intensely focused on the company's expansion into GLP-1 weight-loss medication support, specifically through its high-profile partnership with Eli Lilly's Employer Connect platform.
After crossing the milestone of 1 million total members in Q1 2026, the market is evaluating whether Omada can maintain its 30% revenue growth pace while improving unit economics. Management's recent upward revision of full-year guidance suggests growing confidence in the 'GLP-1 Care Track' as a primary driver for achieving consistent profitability.